Effects of ipilimumab on absolute and relative eosinophil counts and co-relationship with incidence of immune-related adverse events in patients with malignant melanoma.
Phase of Trial: Phase IV
Latest Information Update: 22 Jul 2014
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 22 Jul 2014 New trial record
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.